PHILADELPHIA — Findings from a study conducted in Peru indicate
significant therapeutic implications for the management of enterocolitis, and
continued surveillance across all areas in the country is needed to guide
efficient antimicrobial use, according to a presenter here.
Researchers assessed 4,652 stool samples for Campylobacter species types
from 2001 to 2010 and tested susceptibilities to azithromycin, ciprofloxacin
and erythromycin.
Eighty-two percent of isolates tested positive for Campylobacter jejuni,
11% for C. coli and 7% for other Campylobacter species types.
During the 10-year study period, the prevalence of ciprofloxacin
resistance increased from 46% to 92% among isolates obtained from Lima.
Similarly, resistance to ciprofloxacin increased from 50% to 86% in the Cusco
region of Peru and from 19% to 38% in isolates obtained from Iquitos.
Only 1% of isolates from Lima and 2% of isolates from the Cusco region
were resistant to azithromycin. Resistance to erythromycin was only 1% among
isolates from Lima and none from the Cusco region.
Conversely, the researchers observed an increase in azithromycin
resistance from 3% to 14% and erythromycin resistance from 3% to 17% in
isolates from Iquitos, Peru.
For more information:
- Pollett S. #79. Presented at: the American Society of Tropical
Medicine and Hygiene 60th Annual Meeting; Dec. 4-8, 2011; Philadelphia.
Disclosure: The researchers report no relevant financial
disclosures.